Ardennes Biosciences

Ardennes Biosciences is a pre-clinical stage biotechnology company focused on transforming the landscape of hematopoietic stem cell (HSC) therapies. The company's primary mission is to develop engineered HSCs that can be transplanted without the need for traditional, highly toxic conditioning regimens such as intensive chemotherapy or total body irradiation. By creating engineered stem cells, Ardennes aims to enable safer and more effective 'immune system reboots' for patients suffering from refractory autoimmune diseases and various blood cancers. Founded by leaders in stem cell biology and backed by top-tier venture capital firms like 5AM Ventures and Abingworth, the company is positioned at the intersection of cell engineering and regenerative medicine. Ardennes is currently advancing its platform technology to move its lead candidates toward clinical evaluation.